Bold Ideas.
Stories. Insights.

Belinda Ephraim 8/26/26 Belinda Ephraim 8/26/26

X-Market Fit Is Bollocks

A note to founders building critical industrial tech on why product market fit is not the right pathway to commercialize and scale their companies.

Belinda Ephraim 7/6/26 Belinda Ephraim 7/6/26

The Flinch We Forgot

A letter to America at two hundred and fifty… and the two fears hiding inside every investment we make.

TENSEUR Capital 11/3/25 TENSEUR Capital 11/3/25

Beyond the AI Hype

Software no longer eats the world. Over the past two decades, we forgot what built Silicon Valley. While everyone chases the next AI software startup, real alpha is hiding in plain sight at the gritty intersection where electrons meet metal, data meets orbit, and policy meets production. The AI infrastructure race isn't happening in the cloud or billion-dollar enterprise data centers. It's happening in contested electromagnetic spectrums, bioengineered sensory systems, and the convergence of material science and artificial intelligence at the edge.

TENSEUR Capital 8/1/25 TENSEUR Capital 8/1/25

Industrial AgTech Gold

Extracting $300BN industrial biomass into AgTech gold, unlocking new revenue streams for F500 agro-processors, pharma, and cosmeceutical enterprises.

TENSEUR Capital 11/14/24 TENSEUR Capital 11/14/24

AI, Robots, and Rolexes

Join us for an illuminating conversation, as we explore the transformation of American #manufacturing through the lens of #robotics integration and automation with Dan Allford of ARC Specialties | The NEO Industrialist Podcast, a TENSEUR Capital production

TENSEUR Capital 8/1/24 TENSEUR Capital 8/1/24

How The World Ran Out of Everything

How global supply chains work, and why they broke, with Peter S. Goodman, a New York Times reporter who covers the global economy.

TENSEUR Capital 7/1/24 TENSEUR Capital 7/1/24

The Factories of the Future

From 2012 to 2018, Will Drewery built and led capex procurement of Tesla’s $3.5BN machinery for the Model S, Model X, and Model 3 production lines. At Diagon, Will is equipping the factories of the future.

OUR LIMITED PARTNERS

SEE THEM FIRST. WITH US.

TENSEUR is for investors who will stay the whole way: from a tested technology, through deployment at scale, to a high-growth company that lasts.

We invest, from a pooled fund, on behalf of:

Industrial corporates without a venture arm: a Silicon Valley manager investing in frontier industrial technologies, and an early view of the companies most likely to enter your value chain as suppliers, partners, or acquisition candidates.
Foundations, endowments, and sovereign wealth funds: patient capital matched to industrial time, with grants and other non-dilutive capital alongside equity when they help a company reach its next milestone.
Funds of funds and GP seeding programs: a focused first fund with a defined Technology Readiness Level 5 entry gate, led by a GP who underwrites like a lender.
Family offices and qualified individual investors: access to seed-stage critical industrial technology through a pooled fund.

You are early because the company is not obvious yet. You are not early because the idea is untested. Whether you are allocating to private markets or considering an anchor commitment to a first-time fund, we will be as direct and as careful as we would want someone to be with us.

TENSEUR Fund I at a Glance

Fund Overview

Investment Stage: Seed-stage industrial deep technology startups with TRL 5+ prototypes.
Geographical Focus: Primarily U.S.-based.
Investment Exclusions: TENSEUR does not invest in software businesses, including SaaS, computational biology platforms, and computational materials platforms, whose primary asset is code sold to discover, operate, monitor, or optimize systems they do not own or make. TENSEUR also does not invest in consumer products or consumer hardware, fintech, crypto, gambling, video games, cannabis, or tobacco. It does not invest in companies whose primary product is a weapon designed to cause lethal harm. Dual-use companies, whose frontier technologies serve commercial markets and mission-driven organizations alike, are within scope.
A therapeutics company may run quantum simulations to design the molecules it develops. A semiconductor company, fabless or integrated, may write its own firmware. A quantum company may write control software for machines it builds. These are not software companies. The exclusion applies to businesses whose only value is the software layer itself.

Investor and Deployment Profile

Investor Archetypes: Industrial corporates, foundations, endowments, sovereign wealth funds, funds of funds and GP seeding programs, family offices, and qualified individual investors.

Investment Parameters and Logistics

Commitments Currently Discussed: $50,000 to $5,000,000 (median allocation: $300,000).
Ways to Invest: Cash, trusts, entities, IRAs, 401(k), or non-U.S. structures.
Compliance: Prospective limited partners should expect third-party verification of accredited investor status, KYC and AML review, and CFIUS-related screening before any interest is issued. The third-party fund administrator would likely repeat those screens annually. A subscription is not complete until those initial screens are completed and the Governing Documents fully executed.

Risk and Disclosures

Liquidity & Capital Loss: Investors may lose all or a substantial amount of their investment in the Fund as a result of identified and/or unidentified risks.
Suitability: An investment in the Fund is not suitable for non-accredited investors.

For illustrative purposes only. Final terms and conditions are strictly subject to definitive subscription documents.

INTERESTED IN LEARNING MORE? BOOK AN LP MEETING.

The information in this website has been prepared by TENSEUR CAPITAL VECTOR COLLECTIVE PBLLC (the “Firm”) solely to determine preliminary investor interest in TENSEUR Fund I L.P. (the “Fund”). This document is not an offer or solicitation, and may not be used or relied upon in connection with any offer or solicitation, with respect to the Fund. Any such offer or solicitation will be made only through the Fund’s final Amended and Restated Limited Partnership Agreement and Subscription Agreement (collectively, the “Governing Documents”), which will be made available upon request to qualified investors.

Prospective investors should carefully review the Governing Documents, including the risks and conflicts of interest described therein, before making an investment decision with respect to the Fund. Investors may lose all or a substantial amount of their investment in the Fund as a result of identified and/or unidentified risks. An investment in the Fund may not be suitable for certain investors.

No person has been authorized to make any statement regarding the Fund other than as contained in the Governing Documents, and no such statements, if made, may be relied upon. Prospective investors must rely solely on the terms of the Governing Documents in determining whether to invest in the Fund. The information set forth herein is not part of or supplemental to the Governing Documents and is qualified in its entirety by the more detailed information in the Governing Documents.

The Firm reserves the right to modify any of the terms of the offering and/or the limited partnership interests described herein. The contents of this document are not to be considered legal, business, tax or other advice, and each prospective investor should consult its own attorney and business, tax and other advisors as to legal, business, tax and other matters related to an investment in the Fund. The information set forth in this document is current as of September 2026, and the Firm is not assuming any obligation to update or otherwise revise such information.

Certain information contained herein has been obtained from third parties. While such sources are believed to be reliable, none of the Fund, its general partner, the Firm or their respective members or affiliates (collectively, the “Firm Parties”) assume any responsibility for the accuracy or completeness of such information or of any other information contained in this document. The views expressed herein are the subjective opinions of the Firm, may differ from the views of other market participants and are subject to change without notice to prospective investors.

The endorsements of the Firm referenced herein were made by third parties (i) that are not prior or current investment advisory clients of the Firm and (ii) that may or may not have invested into any investment vehicles formed or managed by the Firm. The endorsements do not necessarily reflect the opinions of all similarly situated persons. The inclusion of any third-party firm and/or company names, brands or logos does not imply an affiliation with those firms or companies or that such firms or companies have endorsed any of the Firm Parties.

Certain returns set forth herein are target returns that do not represent the performance of any actual investment or investment portfolio and, accordingly, are hypothetical. The preparation of hypothetical returns is based on underlying assumptions that are not applicable to non-hypothetical performance. There can be no assurance that such assumptions are reasonable or fully stated herein, and the use of different assumptions would produce different results. The preparation of hypothetical returns also includes the use of subjective judgments. For the foregoing and other similar reasons, the comparability of hypothetical performance to the actual performance of any fund or other investment vehicle is limited, and prospective investors should not unduly rely on any such information in making an investment decision. Nothing contained herein should be considered a prediction or projection of future performance. There is no assurance that the Fund will make any profit or will be able to avoid incurring significant losses.

References herein to “expertise,” any party being an “expert,” or awards received, degrees conferred or other particular skill sets are based solely on the belief of the Firm and/or are provided only to indicate proficiency as compared to an average person. Such references should not be construed or relied upon as an indication of future performance or other future outcomes. Similarly, references herein to “unique” and similar expressions are also based solely on the belief of the Firm and/or are not intended to refer to an exclusively singular practice but to the possession of characteristics of distinctiveness not found universally in the market.

Any references herein to the expertise of, or to awards conferred on, any Firm Party are included only to indicate proficiency as compared to the average person and in no way modify the exculpation or standard of care provisions in the Governing Documents. Similarly, the term “unique” and other similar expressions are based solely on the views of the Firm and are not intended to refer to an exclusively singular practice.

Certain statements in this document constitute forward-looking statements, which may be identified by the use of forward-looking terminology such as “may,” “will,” “seek,” “should,” “expect,” “anticipate,” “project,” “estimate,” “intend,” “continue,” “target,” “plan” or “believe” or the negatives thereof or other variations thereon or comparable terminology. Such forward-looking statements, including the intended actions and performance objectives of the Firm Parties referenced herein, involve known and unknown risks, uncertainties, and other important factors that could cause the actual results, performance, or achievements of the Firm Parties to differ materially from any future results, performance, or achievements expressed or implied by such forward-looking statements. All forward-looking statements are subject to change without notice, and no representation or warranty is made as to the reasonableness of any such forward-looking statements.

This document has not been filed with or reviewed by the Securities and Exchange Commission, any state securities commission or any other regulatory authority, and no such authorities have passed upon or endorsed the merits of an investment in the Fund or the accuracy of the information herein. Any representation to the contrary is a criminal offense.

Each recipient acknowledges and agrees that the contents of this document constitute the proprietary and confidential information of the Firm Parties that (1) the Firm Parties derive independent economic value from not being generally known and (2) are the subject of reasonable efforts to maintain their secrecy. The recipient further acknowledges that the contents of this document are a trade secret, the disclosure of which is likely to cause substantial and irreparable competitive harm to the Firm Parties. The distribution or reproduction of this document in whole or in part, the divulgence of any of its contents, or the use of the contents for any purpose other than to determine interest for an investment in the Fund is strictly prohibited. This document must be returned to the Firm upon request.

TENSEUR

©2026. All rights reserved. TENSEUR Capital

Book an LP Meeting | Legal | Privacy Policy | FAQ